



# ISSX 9TH INTERNATIONAL MEETING ISTANBUL 2010

September 4-8, İstanbul Convention and Exhibition Centre

## What is ISSX ?

The International Society for the Study of Xenobiotics (ISSX) is the premier international scientific organization for researchers interested in the study of xenobiotics (drugs, agricultural and industrial chemicals, environmental contaminants and other exogenous substances). The society serves to promote scientific development and to foster communications among researchers. ISSX hosts an International Meeting in every three years.

## This meeting aims

to bring together many internationally renowned scientists and young scientists from academia and industry, working on drug/xenobiotic research in diverse fields including basic and clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal chemistry, drug discovery and development, molecular and structural biology and genetics, and other related areas .

All accepted abstracts will be published in a special supplemental issue of *Drug Metabolism Reviews*.

## Forum

Istanbul ISSX Meeting Includes

- Short courses
- Plenary lectures
- Symposia
- Poster presentations
- Short oral presentations selected from abstracts
- Job placement service (employment opportunities)
- Presentations of society awards
- Industry-supported symposia
- Competition for best poster presentations by predoctoral and postdoctoral researchers
- Student networking
- Commercial exhibitions
- Society banquet
- Social programme

## Meeting Organizing Chair

**Prof. Dr. Emel Arinç**  
Turkish Academy of Sciences  
Middle East Technical University  
Ankara, Turkey

## Meeting Organizing Committee

Arinç, Emel (Turkey)  
Beaune, Phillippe H. (France)  
Hodgson, Ernest ( USA )  
Ingelman-Sundberg, Magnus (Sweden)  
Johnson, Eric F. (USA)  
Kaminsky, Laurence S. (USA)  
Kroemer, Heyo K. (Germany )  
Meyer, Urs A. ( Switzerland )  
Prough, Russell A. ( USA )  
Serabjit-Singh, Cosette J. ( USA )  
Şen, Alaattin (Turkey)  
Testai, Emanuela (Italy)

## International Scientific Advisory Board

Archakov, Alexander I. (Russia)	Melli, Mehmet (Turkey)
Beaune, Phillippe H. (France)	Miners, John (Australia)
Dizdaroğlu, Miral (USA)	Nebert, Daniel (USA)
Doehmer, Johannes (Germany)	Oesch, Franz (Germany)
Eichelbaum, Michel (Germany)	Prough, Russell A. (USA)
Gonzalez, Frank (USA)	Sugiyama Yuichi (Japan)
Gorrod, John (UK)	Ingelman-Sundberg, Magnus (Sweden)
Johnson, Eric F. (USA)	Utrecht, Jack (Canada)
Kaminsky, Laurence S. (USA)	Vereczkey, Lazlo (Hungary)
Kapitulnik, Jaime (Israel)	Vermeulen Nico P.E. (Netherlands)
Lu, Anthony (USA)	Yost, Gerald S. (USA)

## Scientific Sessions

### Prediction and Mechanisms of Adverse Drug Reactions

Chair: *Jack Utrecht (Canada)*

### Structure and Function of Drug Metabolizing Enzymes & Transporters

Chair: *Eric Johnson (USA)*

### Gene Regulation of Drug Metabolizing Enzymes by Nuclear Receptors

Chair: *Patrick Maurel (France)*

### Clinical Pharmacology of Drug Transport: From Bench to Bedside

Chair: *Heyo Kroemer (Germany)*

### Novel Extrahepatic Cytochromes P450 with Endogenous and Exogenous Functions

Chair/Co-chair: *Garold S. Yost (USA)/Jorge Capdevila (USA)*

### Pharmacogenomics of Cancer Treatment - Emerging Era of Translational Medicine

Chair/Co-chair: *Emel Arinç (Turkey)/Matthias Schwab (Germany)*

### Nutrition and Cancer Prevention

Chair/Co-chair: *Young-Joon Surh (South Korea)/Ömer Küçük (USA)*

### Pharmacoeepigenetic and MicroRNA-dependent Control of Drug Metabolism and Action

Chair/Co-chair: *Magnus Ingelman-Sundberg (Sweden)/Tsuyoshi Yokoi (Japan)*

### Oxidative Stress, DNA Damage, Repair and Biological Consequences

Chair: *Miral Dizdaroğlu (USA)*

### Biotechnology: Bioengineering of New Enzymes

Chair: *Elizabeth Gilliam (Australia)*

### Toxicogenomics and Xenobiotic/Drug Safety: Present Status & Perspectives

Chair/Co-chair *Nico P.E. Vermeulen (Netherlands)/Laura Suter-Dick (Switzerland)*

### Contemporary Issues in Drug Research and Therapeutics

Chair/Co-chair *Anthony Y. H. Lu (USA)/Alexander I. Archakov (Russia)*

### Environmental Toxicology and Health

Chair/Co-chair: *Ernest Hodgson (USA)/Emanuela Testai (Italy)*



**The abstract submission date is May 14, 2010**

**Registration fee for member students and post-doctoral fellows: only 175 \$**

**Further info: [www.issx.org](http://www.issx.org)**





# ISSX 9TH INTERNATIONAL MEETING ISTANBUL 2010

September 4-8, İstanbul Lütfi Kırdar Convention and Exhibition Centre

## PLENARY SESSIONS AND SYMPOSIA

### What is ISSX?

The International Society for the Study of Xenobiotics (ISSX) is the premier international scientific organization for researchers interested in the study of xenobiotics (drugs, agricultural and industrial chemicals, environmental contaminants and other exogenous substances). The society serves to promote scientific development and to foster communications among researchers. ISSX hosts an International Meeting in every three years.

### This meeting aims

To bring together many internationally renowned scientists and young scientists from academia and industry, working on drug/xenobiotic research in diverse fields including basic and clinical pharmacology and therapeutics, toxicology, oncology, endocrinology, physiology, biochemistry, medicinal chemistry, drug discovery and development, molecular and structural biology and genetics, and other related areas.

All accepted abstracts will be published in a special supplemental issue of *Drug Metabolism Reviews*.

### Forum

#### Istanbul ISSX Meeting Includes

- Short courses
- Plenary sessions & Symposia
- Poster presentations
- Short oral presentations selected from abstracts
- Job placement service
- Presentations of society awards
- Industry-supported symposia
- Competition for best poster presentations by predoctoral and postdoctoral researchers
- Student networking
- Commercial exhibits
- Society banquet

### Meeting Organizing Chair

Prof. Dr. Emel Arinç  
Turkish Academy of Sciences  
Middle East Technical University  
Ankara, Turkey

### Meeting Organizing Committee

Arinç, Emel (Turkey)  
Beaune, Phillippe H. (France)  
Hodgson, Ernest (USA)  
Ingelman-Sundberg, Magnus (Sweden)  
Johnson, Eric F. (USA)  
Kaminsky, Laurence S. (USA)  
Kroemer, Heyo K. (Germany)  
Meyer, Urs A. (Switzerland)  
Prough, Russell A. (USA)  
Serajit-Singh, Cosette J. (USA)  
Şen, Alaattin (Turkey)

### International Scientific Advisory Board

Archakov, Alexander I. (Russia)	Miners, John (Australia)
Beaune, Phillippe H. (France)	Nebert, Daniel (USA)
Dizdaroglu, Miral (USA)	Oesch, Franz (Germany)
Doehmer, Johannes (Germany)	Prough, Russell A. (USA)
Eichelbaum, Michel (Germany)	Sugiyama Yuichi (Japan)
Gonzalez, Frank (USA)	Ingelman-Sundberg, Magnus (Sweden)
Gorrod, John (UK)	Uetrecht, Jack (Canada)
Johnson, Eric F. (USA)	Vereczky, Lazlo (Hungary)
Kaminsky, Laurence S. (USA)	Vermeulen Nico P.E. (Netherlands)
Kapitulnik, Jaime (Israel)	Yost, Gerald S. (USA)
Lu, Anthony (USA)	
Melli, Mehmet (Turkey)	

### Short Courses

- 1: Current Application of Pharmacokinetic-Pharmacodynamic Modeling During Drug Discovery & Development**  
Organizer: Bill J. Smith, *Development Strategies Group, Pharmacokinetics, Dynamics&Metabolism, Pfizer, La Jolla, USA*
- 2: Stem Cell Issues: Basic Science and Practical Approaches**  
Organizer: Emin Kansu, *Dept. of Oncology, School of Medicine, Hacettepe University, Ankara, Turkey*
- 3: Oxidative DNA Damage: Mechanisms and Measurement**  
Organizer: Miral Dizdaroglu, *National Institute of Standards and Technology, Chem. Sci. and Tech. Lab, Gaithersburg, MD, USA*
- 4: Hands-On Workshop on Predicting Oral Drug Bioavailability and Its Interindividual Variability: Interplay between Formulation, Drug Permeability and Metabolism**  
Organizer: Amin Rostami, *School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK*

### Keynote Lectures

- Drug Transporters: Roles in New Drug Discovery and Development**  
Yuichi Sugiyama, *Pharmaceutical Sciences, Univ. of Tokyo, Japan*
- Transporter Mediated Toxicity: The role of Mitochondrial and Plasma Membrane Transporters**  
Jashvant Unadkat, *Dept. of Pharmaceutics, Univ. of Washington, Seattle, WA, USA*

### Prediction and Mechanisms of Adverse Drug Reactions

Organizer : Jack Uetrecht (Canada)

#### Use of Animal Models for the Study of ADRs

Jack Uetrecht, *Canada Research Chair in Adverse Drug Reactions, Faculty of Pharmacy, Univ. of Toronto, Canada*

#### Understanding Idiosyncratic Hepatotoxicity: From Man to Mouse to Computer

Paul B. Watkins, *University of North Carolina Institute for Drug Safety Sciences, Chapel Hill, NC, USA*

#### Genetic Risk Factors for ADRs

Munir Pirmohamed, *Pharmacogenetics, Centre for Drug Safety Science, Dept. of Pharmacology, Univ. of Liverpool, UK*

#### ADR Prediction: an Evolving Industry Perspective

Bruce D. Car, *Vice President, Discovery Toxicology, Bristol-Myers Squibb, Princeton, NJ, USA*

### Toxicogenomics and Xenobiotic/Drug Safety: Present Status & Perspectives

Organizers : Nico P.E. Vermeulen (Netherlands)/ Laura Suter-Dick (Switzerland)

#### Strategic Applications of Toxicogenomics in Early Drug Discovery

James L. Stevens, *Senior Research Fellow, Lilly Research Laboratories, IN, USA.*

#### Toxicogenomics: a Predictive Tool in Toxicology and Drug Development

Laura Suter-Dick, *Investigative Toxicology, Non Clinical Safety, F. Hoffmann-La Roche, Basel, Switzerland.*

#### Epigenomics - Impact for Drug Safety Sciences

Jonathan G. Moggs, *Novartis Inst. for BioMedical Research, Translational Sciences, Preclinical Safety, Switzerland*

#### Biomarkers for Adverse Drug Reactions: Proteomics and Metabolomics Strategies

Kevin B. Park, *Dept. of Pharmacology & Therapeutics, University of Liverpool, UK*

### Pharmacogenomics of Cancer Treatment-Emerging Era of Translational Medicine

Organizers : Emel Arinç (Turkey)/Matthias Schwab (Germany)

#### Role of Pharmacogenomics in the Treatment of Breast Cancer

David Flockhart, *Division of Clinical Pharmacology, Indiana Univ. School of Medicine, Indiana, USA*

#### Pharmacogenetics of Thiopurins in the Treatment of Acute Childhood Leukemia

Matthias A. Schwab, *Dept. of Clinical Pharmacology, Dr Margarete Fischer-Bosch Inst, Stuttgart, Germany*

#### Mechanisms of Resistance and Clinical Results of Second Generation Tyrosine Kinase Inhibitors in CML Patients Resistant/Intolerant to Imatinib

Tim H. Brümmendorf, *Dept. Hematology and Oncology, Univ. Hospital Aachen, Aachen, Germany*

#### Pharmacogenomics of Colorectal Cancer Including Prognostic and Predictive Biomarkers

Sabine Tejpar, *Digestive Oncology, Center for Human Genetics, Univ. Hospital Gasthuisberg, Leuven, Belgium*

### Novel Extrahepatic P450s with Endogenous and Exogenous Functions

Organizers : Garold S. Yost (USA)/Jorge Capdevila (USA)

#### Lung P450 Expression, Bioactivation, and Mechanism-Based Inactivation by Glucocorticoids and Mutagens

Gary S. Yost, *Dept. of Pharmacology and Toxicology, Univ. of Utah, Salt Lake City, UT, USA*

#### Function and Regulation of CYP2S1

Oliver Hankinson, *Dept. of Pathology and Laboratory Medicine, Los Angeles, CA, USA*

#### The Arachidonic Acid Epoxygenases: Functional Roles and Relevance to the Pathophysiology of Hypertension and Tumor Angiogenesis

Jorge Capdevila, *Dept. of Medicine, Vanderbilt University Medical School, Nashville, TN, USA*

#### Essential Role of Cytochrome P450s in Vitamin D Signaling

Inge Schuster, *Institute of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria*

### Contemporary Issues in Drug Research and Therapeutics

Organizers : Anthony Y. H. Lu (USA)/Alexander I. Archakov (Moscow/Russia)

#### Safety and Efficacy of Amphiphilic Cyclodextrins for Drug Delivery

A. Atilla Hincal, *IDE Drug Information Consultancy and Education Ltd Co., Ankara, Turkey*

#### Application of Nanotechnology in Cancer Therapy and Imaging

Dong M. Shin, *Hematology and Medical Oncology, Winship Cancer Inst., Emory Univ., Atlanta, GA, USA*

#### Nanobiotechnology in Clinical Proteomics

Alexander I. Archakov, *Russian Academy of Sciences, Moscow, Russia*

#### Pharmacologically Regulated Stem Cell Therapy

C. Anthony Blau, *Inst. for Stem Cell and Regenerative Medicine, Univ. of Washington, Seattle, WA, USA*

### Oxidative Stress, DNA Damage, Repair and Biological Consequences

Organizer : Miral Dizdaroglu (USA)

#### Oxidative DNA Damage, DNA Repair Enzyme NEIL1, Polymorphisms and Cancer

Miral Dizdaroglu, *National Inst. of Standards and Technology, Chem. Sci. and Technology Lab, MD, USA*

#### Oxidative Stress and Antioxidants, Beneficial or Pathological

Bary Halliwell, *Department of Biochemistry, National University of Singapore, Singapore*

#### Role of Transcription Coupled DNA Repair in Human Disease

Philip Hanawalt, *Department of Biology, Stanford University, Stanford, CA, USA*

#### DNA Repair of Oxidative Damage: From Mechanisms to Cancer Risk

Eugenia Dogliotti, *Istituto Superiore di Sanita Rome-Italy*

### Environmental Toxicology and Health

Organizers : Ernest Hodgson (USA)/Emanuela Testai (Italy)

#### Metabolic Interactions of Agrochemicals and Human Health

Ernest Hodgson, *Dept. of Environmental and Molecular Toxicology, NCSU, Raleigh, NC, USA*

#### Human Health Risk Assessment Associated with Cyanotoxin Exposure

Emanuela Testai, *Istituto Superiore di Sanita, Environmental and Primary Prevention Dept., Rome, Italy*

#### Heavy Metals in the Environment and Human Health

Claudia Miero, *Chemistry Dept., University of Aveiro, Aveiro, Portugal*

#### Dialkylanilines are Ubiquitous and Potently Toxic and Mutagenic via Multiple Metabolic Pathways

Steven R. Tannenbaum, *Dept. of Biological Engineering and Chemistry, MIT, Cambridge, MA, USA*

### Gene Regulation of Drug Metabolizing Enzymes by Nuclear Receptors

Organizer : Patrick Maurel (France)

#### AhR and Gene Regulation

Yoshiaki Fujii-Kuriyama, *University of Tsukuba, TARA, Tsukuba, Ibaraki, Japan*

#### Nuclear Receptors and Gene Regulation

David D. Moore, *Baylor College of Medicine, Dept. of Molecular and Cellular Biology, Houston, TX, USA*

#### CAR and Gene Regulation

Masahiko Negishi, *NIEHS/NIH, Pharmacogenetics Section, Research Triangle Park, NC, USA*

#### PXR and CAR and the Regulation of Gene Involved in the Metabolism of Anticancer Drugs

Jean-Marc Pascussi, *University of Montpellier 1, INSERM, Montpellier, France*

### Structure and Function of Drug Metabolizing Enzymes & Transporters

Organizer : Eric F. Johnson (USA)

#### Analysis of P450 Structure-Functions Relations in Drug Metabolism Using X-ray Crystallography

Eric F. Johnson, *Dept. of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA, USA*

#### P450 Structure and Function: Mechanisms of Drug Oxidations

F. Peter Guengerich, *Dept. of Biochemistry, Vanderbilt Univ. School of Medicine, Nashville, TN, USA*

#### Structural Studies of Cholesterol Metabolizing P450s

Irina Pikuleva, *Dept. of Ophthalmology, Case Western Reserve University, Cleveland, OH, USA*

#### Structure of P-Glycoprotein

Geoffrey Chang, *Dept. of Molecular Biology, Scripps Research Institute, La Jolla, CA, USA*

### Clinical Pharmacology of Drug Transport: From Bench to Bedside

Organizer : Heyo Kroemer (Germany)

#### Therapeutic Implications of OATP1B1 Polymorphisms

Mikko Niemi, *Dept. of Clinical Pharmacology, Helsinki University, Finland*

#### Cardiovascular Drug Transport

Heyo K. Kroemer, *Institute of Pharmacology, Ernst Moritz Arndt University, Greifswald, Germany*

#### Regulation of Drug Transporters in Different Disease States and its Toxicological and Clinical Implications

Jose E. Manautou, *Univ. of Connecticut, School of Pharmacy, Pharmacology and Toxicology, CT, USA*

#### Quantification of Transporter/Enzyme Protein in Human Tissue by Mass Spectrometry: A New Path to Pharmacoproteomics

Tetsuya Terasaki, *Dept. of Biochemical Pharmacology and Therapeutics, Tohoku Univ., Tohoku, Japan*

### Nutrition and Cancer Prevention

Organizers: Young-Joon Surh (South Korea)/ Ömer Küçük (USA)

#### Xenobiotic Metabolizing Enzymes as Targets for Nutritional Cancer Chemoprevention

Young-Joon Surh, *Lab of Molecular Carcinogenesis & Chemoprevention, Seoul National Univ., S. Korea*

#### Soy Isoflavones in Prostate Cancer Treatment

Ömer Küçük, *Dept. of Hematology-Oncology, Emory University, Winship Cancer Institute, Atlanta, USA*

#### Chemopreventive and Chemotherapeutic Effects of Curcumin: Molecular and Clinical Aspects

Marc Diederich, *Foundation for Research on Cancer & Blood Dis. Lab. of Mol. & Cell. Biology of Cancer, Luxembourg*

#### Tocopherols and Cancer Prevention

Chung S. Yang, *Laboratory for Cancer Research, College of Pharmacy, Rutgers Univ., NJ, USA.*

### Pharmacoeigenetic and MicroRNA-Dependent Control of Drug Metabolism and Action

Organizers: Magnus Ingelman-Sundberg (Sweden)/Tsuyoshi Yokoi (Japan)

#### Pharmacoeigenetics of Drug Pharmacokinetics

Magnus Ingelman-Sundberg, *Dept. of Pharmacology, Pharmacogenetics, Karolinska Inst., Stockholm, Sweden*

#### MicroRNA Regulation of Drug Metabolizing Cytochromes P450

Miki Nakajima, *Faculty of Pharmaceutical Sciences, Kanazawa Univ., Japan*

#### Epigenetic Control of Ontogenicity of Cytochrome P450 Expression

Xiao-bo Zhong, *Dept. of Pharmacology & Toxicology, The Univ. of Kansas Medical Center, USA*

Oral Presentation 1: TBA

Oral Presentation 2: TBA

### Biotechnology: Bioengineering of New Enzymes

Organizer : Elizabeth Gilliam (Australia)

#### Engineering of GSTs for Biocatalysis

Bengt Mannervik, *Dept. of Biochemistry and Organic Chemistry, Uppsala University, Uppsala, Sweden*

#### Engineering P450s by Rational Design

Luet-Lok Wong, *University of Oxford, Department of Chemistry, Oxford, UK*

#### Directed Evolution of Xenobiotic-Metabolising Enzymes

Elizabeth Gilliam, *School of Biomedical Sciences, University of Queensland, Queensland, Australia*

#### Optimization of CYP102A1 for Biocatalysis

Vlada Urlacher, *Institute of Technical Biochemistry, University of Stuttgart, Stuttgart, Germany*

The abstract submission date **May 14, 2010**

Registration fee for member students and post-doctoral fellows: **only 175 \$**  
**Travel grants are available**

Further info: [www.issx.org](http://www.issx.org)

